VEGFA and hypertensive disorder: However, as reports from oncology clinics indicate that hypertension is a major side effect of currently used anti-VEGF agents and because RA patients commonly present with hypertension, it would therefore be prudent to identify an anti-VEGF antiangiogenic agent that does not increase blood pressure for the treatment of RA [10–13].